A novel strategy to generate immunocytokines with activity-on-demand using small molecule inhibitors

ABSTRACT: Cytokine-based therapeutics have been shown to mediate objective responses in certain tumor entities but suffer from insufficient selectivity, causing limiting toxicity which prevents dose escalation to therapeutically active regimens. The antibody-based delivery of cytokines significantly increases the therapeutic index of the corresponding payload but still suffers from side effects associated with peak concentrations of the product in blood upon intravenous administration. Here we devise a general strategy (named "Intra-Cork") to mask systemic cytokine activity without impacting anti-cancer efficacy. Our technology features the use of antibody-cytokine fusions, capable of selective localization at the neoplastic site, in combination with pathway-selective inhibitors of the cytokine sign

SUBMITTER: Ms. Giulia Rotta 

PROVIDER: S-SCDT-10_1038-S44321-024-00034-0 | biostudies-other |

REPOSITORIES: biostudies-other